JPH11503309A - Il−17受容体 - Google Patents
Il−17受容体Info
- Publication number
- JPH11503309A JPH11503309A JP8528655A JP52865596A JPH11503309A JP H11503309 A JPH11503309 A JP H11503309A JP 8528655 A JP8528655 A JP 8528655A JP 52865596 A JP52865596 A JP 52865596A JP H11503309 A JPH11503309 A JP H11503309A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- dna
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記要素: (a)配列番号:2のアミノ酸1〜322のアミノ酸配列を有するタンパク質 をコードするDNA; (b)配列番号:10のアミノ酸1〜320のアミノ酸配列を有するタンパク 質をコードするDNA;および (c)緊縮条件下で(a)又は(b)のDNAにハイブリダイゼーションする ことができるDNA分子であって、IL−17と結合するIL−17Rをコード するDNA分子;並びに (d)(a)、(b)又は(c)のDNAによってコードされるタンパク質の フラグメントであって、IL−17と結合するフラグメントをコードするDNA 分子 から成る群から選択される単離DNA。 2.少なくとも約17ヌクレオチド長さのオリゴヌクレオチドと、少なくと も約25ヌクレオチド長さのオリゴヌクレオチドと、少なくとも約30ヌクレオ チド長さのオリゴヌクレオチドとから成る群から選択される、請求項1記載のD NAフラグメントである単離オリゴヌクレオチド。 3.下記要素: (a)配列番号:2のアミノ酸1〜322のアミノ酸配列を有するタンパク質 をコードするDNA; (b)配列番号:10のアミノ酸1〜320のアミノ酸配列を有するタンパク 質をコードするDNA; (c)(a)又は(b)のタンパク質にアミノ酸配列において少なくとも約7 0%同じであり、IL−17と結合するタンパク質をコードするDNA分子;お よび (d)(a)、(b)又は(c)のDNAによってコードされるタンパク質の フラグメントであって、IL−17と結合するフラグメントをコードするDNA 分子 から成る群から選択される単離DNA。 4.請求項1記載のDNA配列を含む組換え発現ベクター。 5.可溶性IL−17Rを発現する、請求項4記載の組換え発現ベクター。 6.請求項3記載のDNA配列を含む組換え発現ベクター。 7.請求項4記載の発現ベクターによって形質転換される又はトランスフェ クトされる宿主細胞。 8.請求項5記載の発現ベクターによって形質転換される又はトランスフェ クトされる宿主細胞。 9.請求項6記載の発現ベクターによって形質転換される又はトランスフェ クトされる宿主細胞。 10.発現を促進する条件下で請求項7記載の宿主細胞を培養し、IL−1 7Rを回収することを含む、IL−17Rタンパク質の製造方法。 11.発現を促進する条件下で請求項8記載の宿主細胞を培養し、IL−1 7Rを回収することを含む、IL−17Rタンパク質の製造方法。 12.発現を促進する条件下で請求項9記載の宿主細胞を培養し、IL−1 7Rを回収することを含む、IL−17Rタンパク質の製造方法。 13.IL−17と結合する、単離及び精製されたインターロイキン−17 受容体(IL−17R)タンパク質であって、下記要素: (a)配列番号:2のアミノ酸1〜322のアミノ酸配列を有するタンパク質 ; (b)配列番号:10のアミノ酸1〜320のアミノ酸配列を有するタンパク 質; (c)緊縮条件下で(a)又は(b)のタンパク質をコードするDNAにハイ ブリダイゼーションすることができるDNA分子によってコードされるタンパク 質であって、IL−17と結合するタンパク質;および (d)IL−17と結合する、(a)、(b)又は(c)のタンパク質のフラ グメント から成る群から選択されるタンパク質。 14.単離及び精製されたIL−17Rタンパク質であって、 下記要素: (a)配列番号:2のアミノ酸1〜322のアミノ酸配列を有するタンパク質 ; (b)配列番号:10のアミノ酸1〜320のアミノ酸配列を有するタンパク 質; (c)(a)又は(b)のタンパク質のアミノ酸配列に少なくとも約70%同 じであるアミノ酸配列を有し、IL−17と結合するタンパク質;および (d)IL−17と結合する、(a)、(b)又は(c)のタンパク質のフラ グメント から成る群から選択されるタンパク質。 15.可溶性IL−17Rから本質的に成る、請求項14記載の単離及び精 製されたIL−17R。 16.請求項13記載のIL−17Rタンパク質と、適当な希釈剤又はキャ リヤーとを含む組成物。 17.哺乳動物における免疫又は炎症反応を調節する方法であって、請求項 16記載の組成物の有効量を投与することを含む方法。 18.IL−17、IL−17R、IL−17とIL−17Rとの相互作用 、又はこの相互作用のアンタゴニスト若しくは模倣体を検出するための分析キッ トであって、請求項16記載のタンパク質組成物と、検出試薬とを含むキット。 19.IL−17Rと免疫反応性である抗体。 20.モノクローナル抗体である、請求項19記載の抗体。 21.移植レシピエントにおける移植された器官又は移植された組織の拒絶 を抑制する方法であって、請求項16記載の組成物の有効量をレシピエントに投 与することを含む方法。 22.移植レシピエントにおける移植された器官又は移植された組織の拒絶 を抑制する方法であって、移植されるべき器官又は組織を請求項1記載の可溶性 IL−17RをコードするDNAによってトランスフェクトしてから、この器官 又は組織をレシピエントに移植することを含む方法。 23.レシピエントに請求項16記載の組成物を投与することをさらに含む 、請求項22記載の方法。 24.請求項13又は14に記載のIL−17Rタンパク質の、移植レシピ エントにおける移植された器官又は移植された組織の拒絶を抑制するための組成 物の製造への使用。 25.請求項1又は3に記載の可溶性IL−17RをコードするDNAの、 移植レシピエントにおける移植された器官又は移植された組織の拒絶を抑制する ための組成物の製造への使用。 26.請求項1又は3に記載の可溶性IL−17RをコードするDNA及び 請求項13又は14に記載のIL−17Rタンパク質の、移植レシピエントにお ける移植された器官又は移植された組織の拒絶を抑制するために別々に、同時に 又は連続的に投与される、単数又は複数種類の組成物の製造への使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41053595A | 1995-03-23 | 1995-03-23 | |
US08/410,535 | 1995-03-23 | ||
US53876595A | 1995-08-07 | 1995-08-07 | |
US08/538,765 | 1995-08-07 | ||
PCT/US1996/004018 WO1996029408A1 (en) | 1995-03-23 | 1996-03-21 | Il-17 receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11503309A true JPH11503309A (ja) | 1999-03-26 |
JP4373495B2 JP4373495B2 (ja) | 2009-11-25 |
Family
ID=27021039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52865596A Expired - Lifetime JP4373495B2 (ja) | 1995-03-23 | 1996-03-21 | Il−17受容体 |
Country Status (15)
Country | Link |
---|---|
US (9) | US5869286A (ja) |
EP (1) | EP0817847B2 (ja) |
JP (1) | JP4373495B2 (ja) |
KR (1) | KR100467998B1 (ja) |
AT (1) | ATE279517T1 (ja) |
AU (1) | AU696775B2 (ja) |
CA (1) | CA2215394C (ja) |
DE (1) | DE69633617T3 (ja) |
DK (1) | DK0817847T4 (ja) |
ES (1) | ES2229264T5 (ja) |
MX (1) | MX9707021A (ja) |
NO (1) | NO974258L (ja) |
NZ (1) | NZ306653A (ja) |
PT (1) | PT817847E (ja) |
WO (1) | WO1996029408A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541195A (ja) * | 1999-04-14 | 2002-12-03 | アメリカ合衆国 | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 |
WO2022244341A1 (ja) * | 2021-05-17 | 2022-11-24 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
DK0817847T4 (da) * | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
WO1997004097A2 (en) * | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
DE69739375D1 (de) * | 1996-11-27 | 2009-06-04 | Immunex Corp | Verfahren zur regulierung der stickstoffmonoxid-erzeugung |
US7005412B1 (en) * | 1996-11-27 | 2006-02-28 | Immunex Corporation | Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins |
US6579520B2 (en) * | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
EP1015488B1 (en) * | 1997-09-17 | 2009-09-09 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
NZ505710A (en) * | 1997-12-22 | 2003-03-28 | Stiftelsen Universitetsforskni | Human Fc receptor genotypes that correspond to the benign/non benign nature of selected autoimmune diseases |
WO1999035263A2 (en) * | 1998-01-09 | 1999-07-15 | Immunex Corporation | Il-17rh dna and polypeptides |
US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
PT1076703E (pt) | 1998-05-15 | 2007-10-10 | Genentech Inc | ''utilizações terapêuticas de polipéptido homólogos de il-17'' |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US8133734B2 (en) * | 1999-03-16 | 2012-03-13 | Human Genome Sciences, Inc. | Kit comprising an antibody to interleukin 17 receptor-like protein |
WO2000064327A2 (en) * | 1999-04-26 | 2000-11-02 | Duke University | Inhibition of complement action |
US6936424B1 (en) | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
JP2016047051A (ja) * | 1999-12-23 | 2016-04-07 | ジェネンテック, インコーポレイテッド | Il−17相同的ポリペプチドとその治療上の用途 |
EP1897947B1 (en) * | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
AU2590901A (en) * | 1999-12-23 | 2001-07-03 | Genentech Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
JP2003526370A (ja) * | 2000-03-16 | 2003-09-09 | アムジェン インコーポレーテッド | Il−17レセプター様分子およびその使用 |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
MXPA02011617A (es) * | 2000-05-24 | 2003-03-10 | Schering Corp | Proteinas de mamiferos receptoras, reactivosy metodos relacionados. |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020146763A1 (en) * | 2000-07-06 | 2002-10-10 | Zeren Gao | Murine cytokine receptor |
EP1332211A2 (en) * | 2000-07-26 | 2003-08-06 | ZymoGenetics, Inc. | Human cytokine receptor |
MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
AU2002225714A1 (en) * | 2000-11-10 | 2002-05-21 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
PL376536A1 (pl) | 2002-08-28 | 2006-01-09 | Immunex Corporation | Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego |
EP1576137A4 (en) * | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
JP4441170B2 (ja) * | 2002-11-28 | 2010-03-31 | 独立行政法人理化学研究所 | S12リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法 |
DK1670511T3 (da) * | 2003-09-15 | 2009-11-23 | Res Dev Foundation | Cripto-antagonisme af activin- og TGF-B-signalering |
JP2008501035A (ja) * | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるil−17の使用 |
WO2005123778A2 (en) | 2004-06-10 | 2005-12-29 | Zymogenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
US20060068434A1 (en) * | 2004-09-21 | 2006-03-30 | Jay Stoerker | Methods and compositions for detecting cancer using components of the U2 spliceosomal particle |
BRPI0516603A (pt) * | 2004-10-18 | 2008-09-16 | Zymogenetics Inc | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos para tratar uma doença imuno-mediada em um paciente em necessidade de tal tratamento, para reduzir a inflamação mediada pela il-17c, para tratar um mamìfero afligido com uma doença inflamatória, e para tratar uma condição patológica em um paciente associada com a atividade de zcytor21 |
JP4868731B2 (ja) | 2004-11-17 | 2012-02-01 | 独立行政法人理化学研究所 | 哺乳動物培養細胞由来の無細胞タンパク質合成システム |
JP4590249B2 (ja) * | 2004-11-17 | 2010-12-01 | 独立行政法人理化学研究所 | 糖タンパク質合成用の無細胞タンパク質合成システム |
JP4787488B2 (ja) * | 2004-11-19 | 2011-10-05 | 独立行政法人理化学研究所 | 直鎖状鋳型dnaを用いた無細胞タンパク質合成方法及びそのための細胞抽出液 |
JP2008532493A (ja) * | 2005-02-14 | 2008-08-21 | ワイス | Il−17fとil−17rとの間の相互作用の特性解析 |
AR052289A1 (es) * | 2005-02-14 | 2007-03-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
EP1933869B1 (en) | 2005-09-01 | 2009-10-14 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
US20070197441A1 (en) * | 2006-02-10 | 2007-08-23 | Rixon Mark W | Truncated il-17ra soluble receptor and methods of using in inflammation |
US7622116B2 (en) | 2006-02-10 | 2009-11-24 | Zymogenetics, Inc. | Method of treating inflammation using soluble IL-17RCX4 |
AU2007261019A1 (en) * | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
FR2910324B1 (fr) * | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
EP2417974A1 (en) | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
WO2008118930A1 (en) * | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
WO2008131315A2 (en) * | 2007-04-20 | 2008-10-30 | Amgen Inc. | Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor |
JP2010534664A (ja) * | 2007-07-23 | 2010-11-11 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Il−17拮抗薬を用いた線維症関連疾患治療の方法及び組成物 |
WO2009042162A2 (en) * | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
EP2213747B1 (en) * | 2007-11-05 | 2021-06-30 | Riken | Method for producing membrane protein |
JP2011514335A (ja) * | 2008-02-21 | 2011-05-06 | アムジェン インコーポレイテッド | Il−17ra−il−17rbアンタゴニストおよび該アンタゴニストの使用 |
CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010108153A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
MX348013B (es) | 2009-05-05 | 2017-05-23 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos. |
US20130064788A1 (en) * | 2009-10-10 | 2013-03-14 | Eleven Biotherapeutics, Inc. | Il-17 family cytokine compositions and uses |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
WO2011088120A1 (en) | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
CN103339145A (zh) | 2010-09-22 | 2013-10-02 | 安姆根有限公司 | 运载体免疫球蛋白及其用途 |
AU2012245231B2 (en) | 2011-04-20 | 2016-10-13 | Amgen Inc. | Autoinjector apparatus |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US20170174772A1 (en) | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
US11618777B2 (en) | 2015-07-31 | 2023-04-04 | Shigeyuki Yokoyama | Method of manufacturing membrane protein and utilization thereof |
EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
SG11202002772VA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Autoinjector with stall and end point detection |
CN114107385A (zh) | 2019-01-17 | 2022-03-01 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
EP4028053A1 (en) | 2019-09-11 | 2022-07-20 | Bausch Health Ireland Limited | Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
US6562333B1 (en) * | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
DK0817847T4 (da) * | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
DE69739375D1 (de) * | 1996-11-27 | 2009-06-04 | Immunex Corp | Verfahren zur regulierung der stickstoffmonoxid-erzeugung |
MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
-
1996
- 1996-03-21 DK DK96912451T patent/DK0817847T4/da active
- 1996-03-21 US US08/620,694 patent/US5869286A/en not_active Expired - Lifetime
- 1996-03-21 WO PCT/US1996/004018 patent/WO1996029408A1/en active IP Right Grant
- 1996-03-21 AU AU55263/96A patent/AU696775B2/en not_active Expired
- 1996-03-21 MX MX9707021A patent/MX9707021A/es unknown
- 1996-03-21 EP EP96912451A patent/EP0817847B2/en not_active Expired - Lifetime
- 1996-03-21 NZ NZ306653A patent/NZ306653A/xx not_active IP Right Cessation
- 1996-03-21 CA CA2215394A patent/CA2215394C/en not_active Expired - Lifetime
- 1996-03-21 PT PT96912451T patent/PT817847E/pt unknown
- 1996-03-21 DE DE69633617T patent/DE69633617T3/de not_active Expired - Lifetime
- 1996-03-21 ES ES96912451T patent/ES2229264T5/es not_active Expired - Lifetime
- 1996-03-21 JP JP52865596A patent/JP4373495B2/ja not_active Expired - Lifetime
- 1996-03-21 AT AT96912451T patent/ATE279517T1/de active
- 1996-03-21 KR KR1019970706470A patent/KR100467998B1/ko not_active IP Right Cessation
-
1997
- 1997-09-15 NO NO974258A patent/NO974258L/no unknown
-
1998
- 1998-02-11 US US09/022,259 patent/US6191104B1/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,253 patent/US6096305A/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,255 patent/US6072033A/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,257 patent/US6197525B1/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,260 patent/US6100235A/en not_active Expired - Lifetime
- 1998-02-12 US US09/022,696 patent/US6072037A/en not_active Expired - Lifetime
-
2007
- 2007-09-19 US US11/901,904 patent/US20090068737A1/en not_active Abandoned
-
2010
- 2010-03-11 US US12/722,477 patent/US20100233186A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541195A (ja) * | 1999-04-14 | 2002-12-03 | アメリカ合衆国 | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 |
WO2022244341A1 (ja) * | 2021-05-17 | 2022-11-24 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
Also Published As
Publication number | Publication date |
---|---|
ES2229264T5 (es) | 2009-12-17 |
AU696775B2 (en) | 1998-09-17 |
ATE279517T1 (de) | 2004-10-15 |
WO1996029408A1 (en) | 1996-09-26 |
DE69633617D1 (de) | 2004-11-18 |
US6100235A (en) | 2000-08-08 |
KR100467998B1 (ko) | 2005-11-25 |
ES2229264T3 (es) | 2005-04-16 |
DE69633617T2 (de) | 2005-11-03 |
EP0817847A1 (en) | 1998-01-14 |
NO974258L (no) | 1997-11-24 |
CA2215394C (en) | 2011-04-26 |
JP4373495B2 (ja) | 2009-11-25 |
US6096305A (en) | 2000-08-01 |
US6072037A (en) | 2000-06-06 |
US6191104B1 (en) | 2001-02-20 |
MX9707021A (es) | 1997-11-29 |
EP0817847B2 (en) | 2009-09-09 |
US20100233186A1 (en) | 2010-09-16 |
DE69633617T3 (de) | 2010-05-20 |
CA2215394A1 (en) | 1996-09-26 |
PT817847E (pt) | 2005-02-28 |
AU5526396A (en) | 1996-10-08 |
DK0817847T3 (da) | 2005-02-14 |
DK0817847T4 (da) | 2009-10-05 |
US20090068737A1 (en) | 2009-03-12 |
US6197525B1 (en) | 2001-03-06 |
NO974258D0 (no) | 1997-09-15 |
EP0817847B1 (en) | 2004-10-13 |
US6072033A (en) | 2000-06-06 |
US5869286A (en) | 1999-02-09 |
NZ306653A (en) | 1999-03-29 |
KR19980703061A (ko) | 1998-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4373495B2 (ja) | Il−17受容体 | |
JP2744821B2 (ja) | インターロイキン4レセプター | |
JP2753287B2 (ja) | インターロイキン―1受容体 | |
CA1341611C (en) | Interleukin-1 receptors | |
US5464937A (en) | Type II Interleukin-1 receptors | |
US5426048A (en) | DNA encoding a fusion receptor for oncostatin M and leukemia inhibitory factor | |
US6410711B1 (en) | DNA encoding CD40 ligand, a cytokine that binds CD40 | |
US5319071A (en) | Soluble interleukin-1 receptors | |
US7309489B1 (en) | Mouse CD40 ligand-specific antibodies and hybridomas | |
AU8656991A (en) | Isolated viral protein cytokine antagonists | |
US7405270B2 (en) | CD40-Ligand lacking native-pattern glycosylation | |
US7273843B2 (en) | Methods of treating allergy by administering interleukin-17 receptor | |
US5716623A (en) | Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules | |
CA1340761C (en) | Interleukin-4-receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080407 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080523 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080708 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090316 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090611 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090821 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090904 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120911 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130911 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130911 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130911 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |